治疗急性支气管炎的阿齐思罗米:一个随机,双盲,受控试验
Arthur T Evans1, Shahid Husain, Lakshmi Durairaj
1Collaborative Research Unit, Department of Medicine, Cook County Hospital and Rush Medical College, Chicago, IL 60612, USA. aevans@cchil.org
Lancet (London, England)
|May 22, 2002
概括
在急性支气管炎治疗中,阿齐思罗米没有比维生素C的好处. 需要进一步的研究来确定这种常见的呼吸道疾病的最佳管理方法.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性支气管炎经常用阿齐思罗米治疗,尽管缺乏支持其有效性的证据.
- 在严格的临床试验中,阿齐思罗米对急性支气管炎的有效性在很大程度上仍未得到研究.
研究的目的:
- 在治疗急性支气管炎时,与维生素C相比,评估阿齐思罗米的疗效.
- 评估急性支气管炎患者与健康相关的生活质量的影响.
主要方法:
- 一项随机,双盲,受控试验与被诊断患有急性支气管炎的成年人进行.
- 参与者在5天的时间内接受了阿齐思罗米或维生素C,以及德克斯特罗米多芬和阿尔布托罗尔.
- 衡量的主要结果是7天后健康相关生活质量的改善,根据治疗意图进行分析.
主要成果:
- 与维生素C相比,在7天的时间里,阿齐思罗米与健康相关的生活质量没有显著改善 (差异为0.03,p=0.8).
- 到第7天恢复正常活动的情况在两组之间是相似的 (89%),没有统计学上显著的差异.
- 副作用的发生频率是可比的,在维生素C组中,由于感知到的副作用而导致的停药数量略高.
结论:
- 在治疗急性支气管炎方面,阿齐思罗米并不优于低剂量维生素C.
- 需要进行更多的研究,以确定急性支气管炎最有效的治疗策略.
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:26Tonsillitis II: Management
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: